BRAF and neoplasm: Furthermore, given the prevalence of BRAF mutations among MSI CRC patients and the positive correlation between the expression of PD-L1, CD8+ tumor- infiltrating lymphocytes and BRAFV600E mutation [246], a further option of treatment is represented by the combination of CPIs and BRAF targeting agents or other agents targeting key players of the MAPK pathway [247].